Syneos Health is a biopharmaceutical solutions organization that accelerates drug development and commercialization through an AI-powered clinical ecosystem. The company combines deep therapeutic expertise with predictive commercial solutions, having supported the development or commercialization of 96% of novel oncology drugs approved by the FDA in the last five years. Syneos Health connects data and human behavior insights to help biopharma clients execute more effectively across the entire product lifecycle.
Funding
Funding not disclosed
Founders
Product
Problem
Biopharmaceutical companies face increasing pressure to accelerate drug development timelines while managing complex clinical trials and commercial launches. Fragmented data, inefficient trial designs, and misaligned development and commercialization strategies often lead to costly delays and suboptimal market performance.
Solution
Syneos Health provides an integrated, AI-powered clinical ecosystem that optimizes trial performance and accelerates decision-making across the drug development and commercialization continuum. The company combines specialized therapeutic expertise with predictive commercial solutions, connecting and harmonizing data to deliver precise, actionable insights. By bringing together clinical development, regulatory, and commercialization capabilities under one operating model, Syneos Health helps biopharmaceutical partners move faster, adapt with agility, and execute more effectively at scale. Their approach emphasizes operating model design over sourcing strategy, enabling more efficient trial execution and improved commercial outcomes.
Target Audience
Primary customers are biopharmaceutical and life sciences companies seeking integrated clinical development, regulatory, and commercialization support to bring new therapies to market efficiently.
Features
- AI-powered innovations that connect and harmonize data across the enterprise for precise, actionable insights
- Deep therapeutic expertise in oncology, having supported 96% of novel oncology drugs approved by the FDA and 93% granted EMA marketing authorization in the last five years
- Lab-to-life service offering extending from preclinical through clinical development, regulatory, and full commercialization
- Predictive commercial solutions that combine human behavior understanding with advanced technologies to reduce risk and accelerate market performance
- FSP (Functional Service Provider) solutions for flexible, scalable clinical development support
- Specialized expertise across central nervous system drugs (89% FDA approval support) and general medicine (92% FDA approval support)